1.Content Determination of Chrysophanol in Yanbao Ⅱ Capsule by HPLC
China Pharmacy 2005;0(19):-
OBJECTIVE:To establish a HPLC method for the content determination of chrysophanol in Yanbao Ⅱ capsule.METHODS:The separation was performed on Agilent C18(150 mm?4.6 mm,5 ?m) column with absolute alcohol-0.1% phosphoric acid (87:13) as mobile phase.The flow rate was 1.0 mL?min-1 and the detection wavelength was set at 254 nm.RESULTS:The linear range of chrysophanol was 0.042 6~0.340 8 ?g(r=0.999 9) with an average recovery of 99.39%(RSD=1.74%,n=6).CON-CLUSION:The method is simple,accurate,sensitive and reproducible for the quality control of YanbaoⅡ capsule.
2.The Accessing Care of The Early Health Interference and The Growth of Infant Times on Premature Very Low-Birth-Weight-Infant
Huizhen CHEN ; Peiqin ZHANG ; Yan ZHANG
Chinese Journal of Perinatal Medicine 2003;0(05):-
Objective To investigate the relationship factor of livability on Premature Very Low-Birth-Weight-Infant (PVLBWL), for refer to evidences that reduce the mortality and the deformity rate. Methods The group 116 PVLBWL cases, being in our hospital hear five years, divide into three team according to the weight, and analyze the review clinical data of the cases (from 1993.1 to 1998.1). Results There are 86 cases that had cured and left hospital in the group. The cure rate is 74.1%(86/116). It is rise along with the weight increase (P
3.Determination of Hydrogen Chloride in Air by Ion-Chromatography
Peiqin HU ; Guixun DAI ; Chunhe ZHANG
Journal of Environment and Health 1993;0(03):-
Objective To make a method for determining the hydrogen chloride in the air by ICS 1 000 ion chromatographic system. Methods Hydrogen chloride in the air of workplace was determinated by using ICS-1 000 ion chromatographic with Ion Pac AS14 chromatographic column, a mixed solution of 3.5 mmol/L Na2CO3 and 1.0 mmol/L NaHCO3 were used as eluent and absorbing solution for the air sample. The sampling was performed at a flow rate of 1.2 ml/min. Results The detection limit was 10 ?g/L, RSDs were 1.65%-3.68% and the rates of recovery were 91.8%-99.7%. Conclusion This method was proved to be accurate, simple, rapid and the disturbance of the other anion and chlorine ion can be avoided. It is also considered as an ideal method to determine the hydrogen chloride in the air.
4.Effects of Shenqi Bufei Decoction on Air Passage and Lung Function of COPD Model Rats with Lung-qi Deficiency
Peiqin ZHANG ; Kui ZHANG ; Yao LIU ; Li LU
China Pharmacy 2001;0(07):-
OBJECTIVE: To observe the effects of Shenqi bufei decoction on air passage and lung function of COPD model rats with lung-qi deficiency.METHODS: Quantitative stimulation with tobacco and SO2 and papain aerosol inhalation were used to establish model COPD rats with lung-qI deficiency.Sixty male rats were randomly divided into: normal group (N),model group(M),low dose treatment group(LT),medium dose treatment group (MT),high dose treatment group (HT),and glucocorticoid treatment group (GCT).Pathomorphological change of lung tissue in rats was observed with light microscope.The thickness of airway wall and smooth muscle layer of the small airway and lung function were measured by means of semi-quantitative image analysis system with lung function detection and analysis system respectively.RESULTS: As compared to N group,in M group the thicknesses of the small airway wall and smooth muscle layer were significantly increased(P
5.Clinical value of the combination of carotid artery ultrasound and TCD in the evaluation of carotid artery stenosis stenting
Hongke WANG ; Xiaoning ZHANG ; Peiqin LIU ; Jun ZHOU ; Xiaoguang ZHANG
Chinese Journal of Nervous and Mental Diseases 2014;(1):31-34
Objective In order to examine the value of the combination of carotid artery ultrasound and Transcrani-al Doppler (TCD) in the evaluation of carotid artery stenosis stenting. Methods Seventy-one carotid stenosis cases con-firmed by digital subtraction angiography (DSA) who had cerebral ischemia symptoms and received stent implantation were reviewed. Carotid artery ultrasound and TCD were adopted to measure the vessel diameter, peak systolic velocity (PSV) of the narrow segment, PSV and pulsatility index (PI) of ipsilateral middle cerebral artery (MCA) before and after the treatment of intravascular stents, and a comparison analysis was made. Results Carotid stent implantation significant-ly improved the inner diameter, PSV of the narrow part, PSV and PI of the MCA on the stenotic side. Inner diameter of the narrow part was 3.13±0.83, 4.77±0.51 and 4.64±0.52 mm at before, one week and one year after the implantation, re-spectively (P<0.05). The PSV of the narrow part was 190.69±113.65, 86.15±30.52 and 90.28±29.79 cm/s at before, one week and one year after the implantation, respectively(P<0.05).PSV of the MCA on the stenotic side was 77.68±14.66, 115.62±22.32 and 108.89±20.29 cm/s at before, one week and one year after the implantation, respectively(P<0.05). PI of the MCA on the stenotic side was 0.81±0.01, 1.07±0.01 and 1.06±0.02 at before, one week and one year after the implantation, respectively (P<0.05). Conclusions The present study demonstrates that the combination of carotid artery ultrasound and TCD can quantitatively detect the vascular structural and hemodynamic improvements following the endo-vascular stenting, indicating that the combination of carotid artery ultrasound and TCD can be used for the accurate as-sessment and follow up of carotid artery stenting treatment.
6.Mesocaval C-shunt plus ligation of splenic artery and esophagogastric (devascularization) in the treatment of type II Budd- Chiari syndrome
Fulin ZHANG ; Bin WANG ; Yongjiang XU ; Yali CHEN ; Peiqin XU
Chinese Journal of General Surgery 1997;0(06):-
Objective To study a new operative method for treatment of hepatic venous occlasion without (associated) pathologic change of inferior vena cava or long-segment stricture. Methods A total of 44 cases of Budd-chiari syndrome with hepatic venous occlusion without pathologic change or long-segment stricture of (inferior) vena cava underwent combined mesocaval C-shunt, ligation of splenic artery, and esophagogastric (devascularization).Results Pre-shunt portal venous pressure was 36cmH2O(31~45 cmH2O, 1cmH2O=0.0098kPa) and post-shunt pressure fell to 26 cmH2O(21~33 cmH2O),the mean reduction was 10 cmH2O. One patient died of liver failure. A slight degree of hepatic encephalopathy occurred in 2patients who recovered after conservative treatment.Chylorrhea occurred in 4 patients, and it spontaneously disappeared 7d to 3.5months after operation. 39 patients(88.6% follow up) were followed up for 6months to 7years , and there was no case of recurrent bleeding nor hepatic encephalopathy. Ascites disappeared in 31cases,and was markedly reduced in 7 cases .The prosthetic grafts were patent as shown by color Doppler ultra sound in all followed-up patients.Conclusions This operation is simple and effective for B-CS with hepatic venous (occlusion) but not associated with inferior vena caval pathologic change or long-segment stricture.
7.Adult cavernous transformation of the portal vein
Yuling SUN ; Xiuxian MA ; Peiqin XU ; Liushun FENG ; Xiaowei DANG ; Ruifang ZHANG ; Yuanyuan ZHOU
Chinese Journal of General Surgery 2010;25(1):28-30
Objective To set up a standard for surgical classification of cavernous transformation of the portal vein (CTPV) and their management strategy according to the classification.Methods The clinical data of 63 CTPV cases were analyzed retrospectively,the classification and the corresponding treatment strategy were evaluated.Results According to the imaging examination,surgical treatment and long-term follow-up,CTPV was classified into four types:Type Ⅰ:cavernous transformation involving main trunk of the portal vein and intrahepatic branches.Portasystemic shunt (mesocaval and splenocaval shunt)(or plus port-azygous devascularization) were used for this type;Type Ⅱ:cavernous transformation in the main trunk and proximal SV or SMV.Portasystemic shunt (mesocaval and splenocaval shunt) or plus portazygous devascularization were applied;Type Ⅲ:cavernous transformation involving the whole portal system.Portopulmonary shunt (splenopneumopexy) or inferior mesenteric-caval shunt plus port-azygous devascularization were suggested;Type Ⅳ:any types aforementioned accompanied by biliary and /or pancreatic abnormalities.The treatment should focus on main symptoms and two-stage operation.Conclusions Doppler ultrasound and multi-slice spiral CT (MSCT) three dimensional (3D) reconstruction are the mainstay for the diagnosis of CTPV;Correct diagnosis,classification as well as individualized management are of great importance in the treatment of adult CTPV.
8.The expression and significance of Glypican-3 in Budd-Chiari syndrome complicated with hepatocellular carcinoma
Xiaowei DANG ; Guanghui NIU ; Lin LI ; Luhao LI ; Youyou LIU ; Kunkun FU ; Song LI ; Zhongjie ZHANG ; Peiqin XU
Chinese Journal of Hepatobiliary Surgery 2018;24(3):162-166
Objective To study the expression and significance of Glypican-3 in Budd-Chiari syndrome (BCS) complicated with hepatocellular carcinoma (HCC).Methods The data of 46 patients with BCS complicated with HCC (the BCS + HCC group) treated in The First Affiliated Hospital of Zhengzhou University from January 2007 to December 2016 were analyzed retrospectively.Another 48 patients with HBV-related HCC (the HBV + HCC group) and 43 patients with hepatic cyst (the hepatic cyst group) were randomly selected as the control groups during the same time period.The differencesin positive rates of Glypican-3 in the liver tissues among the three groups were compared.The BCS + HCC group was further divided into the Glypican-3 positive and Glypican-3 negative subgroups according to the expression of Glypican-3.The differences in gender,age,AFP,HbsAg,Child-Pugh classification,tumor number,extrahepatic metastasis,vascular invasion,Edmondson-Steiner grading and BCLC staging between the two subgroups were compared.The survival time of the two subgroups was compared using the Kaplan-Meier method.Results The expression rates of Glypican-3 in the BCS + HCC group,HBV + HCC group and Hepatic Cyst group were 76.1%,70.8% and 0%,respectively.The levels of Glypican-3 in the BCS + HCC group and the HCC group were significantly higher than that in the hepatic cyst group.The differences were statistically significant (P < 0.05).No statistically significant difference was detected between the BCS + HCC group and the HBV + HCC group (P > 0.05).In the group of patients with BCS + HCC,there was no significant difference in gender,age,AFP,HbsAg,Child-Pugh classification,tumor number and extrahepatic metastasis between the Glypican-3 positive and negative subgroups (P >0.05).However,vascular invasion,Edmondson-Steiner grading and BCLC staging in the Glypican-3 positive subgroup were significantly higher than those in the Glypican-3 negative group,(P < 0.05).The 1-year,3-year and 5-year survival rates were 77.1%,51.0% and 22.8% in the Glypican-3 positive subgroup,compared with 90.9%,63.6% and 45.5% in the Glypican-3 negative subgroup,respectively.There were statistically significant differences between the two groups (P < 0.05).Conclusion Glypican-3 has a stable expression in patients with BCS complicated with HCC,and it is closely related to malignancy of the tumor and prognosis of the patients.
9.Fibroblasts weaken the anti-tumor effect of gefitinib on co-cultured non-small cell lung cancer cells.
Xiao YONG ; Peiqin WANG ; Tao JIANG ; Wenchen YU ; Yan SHANG ; Yiping HAN ; Pingping ZHANG ; Qiang LI
Chinese Medical Journal 2014;127(11):2091-2096
BACKGROUNDNon-small cell lung cancer (NSCLC) is the most common lung malignancy worldwide. The metastatic potential of NSCLC cells has been shown to be associated with the tumor microenvironment, which consists of tumor cells, stroma, blood vessels, immune infiltrates and the extracellular matrix. Fibroblasts can produce numerous extracellular matrix molecules and growth factors. Gefitinib has been evaluated as a first-line treatment in selected patients, and it has shown favorable efficacy especially in NSCLC, but it is not effective for everyone.
METHODSIn this study, we examined the antitumor activity of gefitinib on lung fibroblasts co-cultured of lung cancer cells. A series of co-culture experiments that employed cell counting kit-8 (CCK8), transwells, real-time polymerase chain reaction (RT-PCR) and Western blotting with HFL-1 fibroblasts and A549 human lung carcinoma cells were performed to learn more about tumor cell proliferation, migration and invasion; and to determine any change of epithelial mesenchymal transition (EMT)-associated tumor markers vimentin, matrix metallopro-teinase 2 (MMP2) and chemotaxis cytokines receptor 4 (CXCR4) mRNA levels.
RESULTSA549 cell proliferation in the presence of HFL-1 cells was not significantly increased compared with A549 cells alone, but A549 cell spheroid body formation was increased after co-culture, and treatment with gefitinib increased further. Our study also revealed that fibroblasts attenuated the lung cancer cell inhibition ratio of migration and invasion after gefitinib treatment in vitro. To further study this mechanism, RT-PCR analysis showed that vimentin, MMP2 and CXCR4 mRNA levels were more highly expressed in the lung cancer cells after co-culture, but did not obviously decrease compared with the control cells following gefitinib treatment. This suggests the mechanism by which fibroblasts attenuate gefitinib-induced expression of EMT-associated tumor markers. Finally, our results demonstrated that co-culture with A549 lung cancer cells does not alter the cell cycle distribution of HFL-1 fibroblasts. Furthermore, HFL-1 fibroblasts had no effect on the cell cycle distribution of HFL-1 cells treated with gefitinib.
CONCLUSIONGefitinib has lower anti-tumor activity on A549 lung cancer cells when co-cultured with HFL-1 fibroblasts.
Antineoplastic Agents ; pharmacology ; Carcinoma, Non-Small-Cell Lung ; Cell Line, Tumor ; Cell Proliferation ; drug effects ; Coculture Techniques ; Epithelial-Mesenchymal Transition ; drug effects ; Fibroblasts ; cytology ; drug effects ; Humans ; Lung Neoplasms ; metabolism ; pathology ; Quinazolines ; pharmacology